Abstract
Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) that is highly curable with all-trans retinoic acid (ATRA) plus anthracycline-based cytotoxic chemotherapy. Given the very high activity of arsenic trioxide in relapsed APL, European investigators conducted a prospective, multicenter, randomized, open-label, phase III noninferiority trial comparing induction therapy with ATRA plus arsenic trioxide (AA) versus ATRA plus chemotherapy (AC) …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
